Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.48 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436430 | 1.00 | CYP2C9 (0.51) | CYP2C9ALDH1A1LMNAMAPTESR2 | |
| SCHEMBL7510571 | 0.85 | CYP2C9 (0.47) | CYP2C9ALDH1A1LMNAMAPTCYP3A4 | |
| SCHEMBL8045331 | 0.85 | CYP2C9 (0.47) | CYP2C9ALDH1A1LMNAMAPTCYP3A4 | |
| SCHEMBL28829161 | 0.84 | CYP2C9 (0.47) | CYP2C9ALDH1A1LMNAMAPTESR2 | |
| SCHEMBL11046109 | 0.84 | CYP2C9 (0.46) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL2036212 | 0.83 | CYP2C9 (0.44) | CYP2C9ALDH1A1LMNAMAPTESR2 | |
| SCHEMBL7239625 | 0.83 | CYP2C9 (0.46) | CYP2C9ALDH1A1LMNAMAPTESR2 | |
| SCHEMBL2036211 | 0.83 | CYP2C9 (0.44) | CYP2C9ALDH1A1LMNAMAPTESR2 | |
| SCHEMBL7239619 | 0.83 | CYP2C9 (0.46) | CYP2C9ALDH1A1LMNAMAPTESR2 | |
| SCHEMBL10946281 | 0.83 | MCL1 (0.46) | CYP2C9ALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673521-B1 | DIELECTRIC LAYER COMPRISING COPOLYMER WITH MESOGENIC UNITS | PPG IND OHIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11525087-B2 | Dielectric devices and methods of fabrication | PPG INDUSTRIES OHIO, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20200263092-A1 | DIELECTRIC DEVICES AND METHODS OF FABRICATION | PPG INDUSTRIES OHIO, INC. | 2020-08-20 | — | — | US | disclosed |
| EP-3673521-A1 | DIELECTRIC LAYER COMPRISING COPOLYMER WITH MESOGENIC UNITS | PPG Industries Ohio, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10619099-B2 | Dielectric devices and methods of fabrication | PPG INDUSTRIES OHIO, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| WO-2019040934-A1 | DIELECTRIC LAYER COMPRISING COPOLYMER WITH MESOGENIC UNITS | PPG INDUSTRIES OHIO, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2686401-B9 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2686401-B1 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2016-11-23 | — | — | EP | disclosed |
| EP-2686401-A1 | MESOGEN-CONTAINING COMPOUNDS | Transitions Optical, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8628685-B2 | Mesogen-containing compounds | TRANSITIONS OPTICAL, INC (US) | 2014-01-14 | — | — | US | disclosed |
| WO-2012128944-A1 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20110216273-A1 | MESOGEN-CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110216273-A1 | MESOGEN-CONTAINING COMPOUNDS | BMP2, MYOC, RARG | CYP2C9 2756/4885ALDH1A1 724/4885LMNA 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.